v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Series F Preferred Stock
Stock options and Restricted Stock Units
Employee Stock Purchase Plan
Preferred Stock
Common Stock
Common Stock
Series F Preferred Stock
Additional Paid in Capital
Additional Paid in Capital
Series F Preferred Stock
Additional Paid in Capital
Stock options and Restricted Stock Units
Additional Paid in Capital
Employee Stock Purchase Plan
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2024         14,192 33,061,002              
Beginning balance at Dec. 31, 2024 $ 68,746       $ 0 $ 331   $ 599,881       $ (531,548) $ 82
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Share-based compensation expense     $ 6,813 $ 50           $ 6,813 $ 50    
Issuance of common stock with the Employee Stock Purchase Plan (in shares)           35,513              
Issuance of common stock with the Employee Stock Purchase Plan 238             238          
Warrant exercise - Series F (in shares)             238,500            
Warrant Exercise - Series F   $ 2,385         $ 2   $ 2,383        
Stock option exercise (in shares)           101,597              
Stock Option Exercise 630         $ 1   629          
Net income (loss) 1,069                     1,069  
Unrealized gain on investment adjustments 239                       239
Foreign currency translation adjustments 60                       60
Ending balance (in shares) at Mar. 31, 2025         14,192 33,436,612              
Ending balance at Mar. 31, 2025 80,230       $ 0 $ 334   609,994       (530,479) 381
Beginning balance (in shares) at Dec. 31, 2024         14,192 33,061,002              
Beginning balance at Dec. 31, 2024 68,746       $ 0 $ 331   599,881       (531,548) 82
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) 3,766                        
Unrealized gain on investment adjustments 296                        
Foreign currency translation adjustments 214                        
Ending balance (in shares) at Jun. 30, 2025         14,192 34,955,974              
Ending balance at Jun. 30, 2025 104,986       $ 0 $ 350   631,826       (527,782) 592
Beginning balance (in shares) at Mar. 31, 2025         14,192 33,436,612              
Beginning balance at Mar. 31, 2025 80,230       $ 0 $ 334   609,994       (530,479) 381
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Share-based compensation expense     7,159 50           7,159 50    
Warrant exercise - Series F (in shares)             1,377,275            
Warrant Exercise - Series F   $ 13,773         $ 14   $ 13,759        
Stock option exercise (in shares)           142,087              
Stock Option Exercise 866         $ 2   864          
Net income (loss) 2,697                     2,697  
Unrealized gain on investment adjustments 57                       57
Foreign currency translation adjustments 154                       154
Ending balance (in shares) at Jun. 30, 2025         14,192 34,955,974              
Ending balance at Jun. 30, 2025 104,986       $ 0 $ 350   631,826       (527,782) 592
Beginning balance (in shares) at Dec. 31, 2025         14,192 34,691,671              
Beginning balance at Dec. 31, 2025 111,219       $ 0 $ 347   639,145       (528,848) 575
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Share-based compensation expense     4,876 70           4,876 70    
Issuance of common stock with the Employee Stock Purchase Plan (in shares)           46,008              
Issuance of common stock with the Employee Stock Purchase Plan 389             389          
Stock option exercise (in shares)           43,431              
Stock Option Exercise 230             230          
Repurchase and retirement of common stock (in shares)           (316,023)              
Repurchase and retirement of common stock (3,000)         $ (3)   (2,997)          
Net income (loss) (1,070)                     (1,070)  
Unrealized gain on investment adjustments 45                       45
Foreign currency translation adjustments (49)                       (49)
Ending balance (in shares) at Mar. 31, 2026         14,192 34,465,087              
Ending balance at Mar. 31, 2026 112,710       $ 0 $ 344   641,713       (529,918) 571
Beginning balance (in shares) at Dec. 31, 2025         14,192 34,691,671              
Beginning balance at Dec. 31, 2025 $ 111,219       $ 0 $ 347   639,145       (528,848) 575
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock option exercise (in shares) 215,666                        
Net income (loss) $ 1,598                        
Unrealized gain on investment adjustments (250)                        
Foreign currency translation adjustments (67)                        
Ending balance (in shares) at Jun. 30, 2026         14,192 34,636,252              
Ending balance at Jun. 30, 2026 121,145       $ 0 $ 346   647,791       (527,250) 258
Beginning balance (in shares) at Mar. 31, 2026         14,192 34,465,087              
Beginning balance at Mar. 31, 2026 112,710       $ 0 $ 344   641,713       (529,918) 571
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Share-based compensation expense     $ 5,054 $ 64           $ 5,054 $ 64    
Stock option exercise (in shares)           172,235              
Stock Option Exercise 973             971          
Repurchase and retirement of common stock (in shares)           (1,070)              
Repurchase and retirement of common stock (11)             (11)          
Net income (loss) 2,668                     2,668  
Unrealized gain on investment adjustments (295)                       (295)
Foreign currency translation adjustments (18)                       (18)
Ending balance (in shares) at Jun. 30, 2026         14,192 34,636,252              
Ending balance at Jun. 30, 2026 $ 121,145       $ 0 $ 346   $ 647,791       $ (527,250) $ 258